BioMed Research International

Advances in Prostate Cancer Research and Treatment


Publishing date
19 Sep 2014
Status
Published
Submission deadline
02 May 2014

1Department of Experimental Medicine, Section of Medical Pathophysiology, Food Science and Endocrinology, Sapienza University of Rome, Rome, Italy

2Radiotherapy Unit, Careggi Hospital, University of Florence, Italy

3Paloma Pharmaceuticals, Inc., Neillian Crescent, Jamaica Plain, MA 02130, USA


Advances in Prostate Cancer Research and Treatment

Description

Prostate cancer is one of the most commonly diagnosed cancers in men. Its etiology appears to be related to lifestyle patterns as well as genetic and epigenetic factors. Surgery, radiation therapy, hormonal manipulation, and chemotherapy remain the major milestones for the treatment of localized, locally advanced, or advanced prostate cancer, respectively. However, after these treatments, prostate cancer recurrence or progression is not uncommon. We now have a greater understanding of mechanisms sustaining prostate cancer progression and recurrence although we are aware that the improvement of oncological outcome of men who remain at high risk for systemic failure may be achieved translating the biological knowledge into clinical practice. Obviously, the information so-obtained could not be sufficient to unravel the molecular pathways that govern the mechanisms involved in the resistance to treatments. Hopefully, the knowledge of critical molecular events involved in these biological processes will allows us to identify unique signatures useful to inspire new therapeutic strategies for overcoming the problem of resistance to conventional treatments.

We invite investigators to contribute original research articles as well as review articles that will stimulate the continuing efforts to understand the molecular pathology underlying prostate cancer recurrence and progression, the development of new combinational strategies to treat this condition, and the evaluation of oncological outcomes in a clinical setting. We are particularly interested in articles describing (1) new modalities for clinical characterization of prostate cancer and measuring outcomes from treatment trials; (2) advances in molecular genetics, diagnostic, and imaging; (3) current concepts in the treatment of Pca using ionizing radiation; and (4) measures of quality of life analysis and sexual health. Potential topics include, but are not limited to:

  • Conventional and molecular imaging
  • Radiation safety
  • Clinical and experimental radiobiology
  • Dosimetric analysis of radiation
  • Molecular determinants of sensitivity and resistance to treatments
  • Molecular determinants of tumor progression and recurrence
  • Regulatory role of sexual hormones
  • Nonsurgical treatments
  • Quality of life analysis and sexual medicine
  • Future strategies

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/bmri/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/bmri/pathology/procan/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2014
  • - Article ID 708383
  • - Editorial

Advances in Prostate Cancer Research and Treatment

Lorenzo Livi | Andrea M. Isidori | ... | Giovanni Luca Gravina
  • Special Issue
  • - Volume 2014
  • - Article ID 464869
  • - Research Article

Sex Steroid Metabolism in Benign and Malignant Intact Prostate Biopsies: Individual Profiling of Prostate Intracrinology

Daniele Gianfrilli | Silvia Pierotti | ... | Federica Barbagallo
  • Special Issue
  • - Volume 2014
  • - Article ID 480725
  • - Clinical Study

Intensified Adjuvant Treatment of Prostate Carcinoma: Feasibility Analysis of a Phase I/II Trial

Giovanna Mantini | Sergio Fersino | ... | Vincenzo Valentini
  • Special Issue
  • - Volume 2014
  • - Article ID 380398
  • - Research Article

KCTD11 Tumor Suppressor Gene Expression Is Reduced in Prostate Adenocarcinoma

Francesca Zazzeroni | Daniela Nicosia | ... | Edoardo Alesse
  • Special Issue
  • - Volume 2014
  • - Article ID 909623
  • - Review Article

Bioclinical Parameters Driving Decision-Making of Subsequent Lines of Treatment in Metastatic Castration-Resistant Prostate Cancer

A. Irelli | G. Bruera | ... | E. Ricevuto
  • Special Issue
  • - Volume 2014
  • - Article ID 135048
  • - Research Article

Antitumor Effects of Saffron-Derived Carotenoids in Prostate Cancer Cell Models

Claudio Festuccia | Andrea Mancini | ... | Manuel Carmona
  • Special Issue
  • - Volume 2014
  • - Article ID 890697
  • - Review Article

Novel Tools for Prostate Cancer Prognosis, Diagnosis, and Follow-Up

Andreas Dimakakos | Athanasios Armakolas | Michael Koutsilieris
  • Special Issue
  • - Volume 2014
  • - Article ID 781340
  • - Review Article

Hypofractionation in Prostate Cancer: Radiobiological Basis and Clinical Appliance

M. Mangoni | I. Desideri | ... | L. Livi
  • Special Issue
  • - Volume 2014
  • - Article ID 801473
  • - Research Article

In Vitro Chronic Administration of ERbeta Selective Ligands and Prostate Cancer Cell Growth: Hypotheses on the Selective Role of 3beta-Adiol in AR-Positive RV1 Cells

Alessandra Colciago | Massimiliano Ruscica | ... | Paola Negri-Cesi
  • Special Issue
  • - Volume 2014
  • - Article ID 465175
  • - Clinical Study

Image-Guided Hypofractionated Radiotherapy in Low-Risk Prostate Cancer Patients

Maurizio Valeriani | Alessia Carnevale | ... | Riccardo Maurizi Enrici
BioMed Research International
 Journal metrics
Acceptance rate31%
Submission to final decision67 days
Acceptance to publication30 days
CiteScore3.600
Impact Factor2.276
 Submit

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.